AxeniQ 100UI
Clostridium botulinum toxin type A · 100 units · vacuum-dried powder, single-dose vial. Developed by Genèse Labs, Paris, France.
Original price was: $69.90.$58.90Current price is: $58.90.
- AxeniQ is a high-purity botulinum toxin type A from Genèse Labs, France, with structural integrity verified through SDS-PAGE analysis. It’s designed for a precise diffusion profile and smooth, natural-looking results across facial aesthetic treatments.
- Sourced through licensed Korean distribution channels
- Temperature-controlled handling from our facility to your door
- Batch number and expiry visible before dispatch
- Practitioner support from our team
Professional use only. This product is intended for administration by licensed healthcare practitioners trained in the relevant anatomy and injection technique. By ordering you confirm you are authorised to purchase and handle products of this class in your jurisdiction. Availability and permitted use vary by country — please verify local regulations before ordering.
In accordance with applicable U.S. FDA regulations, this product is not available for purchase or shipment to U.S. addresses through this website. Customers in the United States should obtain botulinum toxin products through appropriately licensed and authorized U.S. distribution channels. A valid medical license or registration certificate is required to process any product-related claim.
Did you like this product? Add to favorites now and follow the product.

(+82) 10 7364 7998 Send a message on WhatsApp.
French-developed botulinum toxin type A, verified by SDS-PAGE
AxeniQ 100UI is a botulinum toxin type A product developed by Genèse Labs of Paris, France — one of the few lines in our range that is not Korean in origin. It is supplied as a vacuum-dried powder in a single 100-unit vial and reconstituted with preservative-free saline immediately before use.
The specification Genèse Labs leads with is batch verification by SDS-PAGE: gel electrophoresis that separates the proteins in a sample by molecular weight. Run on each batch, it confirms the toxin complex has its expected protein profile and has not fragmented or degraded in manufacture. It is a protein-identity and integrity check, not a potency assay.
That is worth knowing precisely because of what it does and does not tell you. It is a real, standard quality-control technique, and publishing it is better than publishing nothing. It is not a clinical outcome, and it is not a substitute for the potency testing every batch must also pass.
Gel electrophoresis confirms the toxin complex's protein profile batch to batch. A protein-integrity check, not a potency test.
Genèse Labs is based in Paris — an alternative to the Korean-origin brands that make up most of this category.
Supplied as a powder rather than a solution, so concentration is chosen to suit the treatment area.
The same formulation in a larger fill, for sessions involving bigger muscle groups.
Why practitioners choose AxeniQ 100UI
Genèse Labs names SDS-PAGE as part of batch release and states the results confirmed the expected molecular weight profile. Most brands in this category describe their standards only in adjectives, so a named method is a point in its favour.
Developed in Paris rather than Seoul. For clinics whose patients ask where a product comes from, that is a straightforward answer to give.
A powder presentation lets you dilute to a higher concentration for larger muscles or a lower one for fine periorbital work.
Available in 100 U and 200 U, so a clinic can match the vial to the session without switching product.
Aesthetic & therapeutic applications
Areas commonly treated with botulinum toxin type A in aesthetic practice. Approval status differs between markets and between brands — always work from the prescribing information registered where you practise.
Lines produced by corrugator and procerus activity. The corrugators sit deep while the procerus is more superficial, so injection depth varies across the points of a single glabellar treatment — one reason the area rewards anatomical familiarity over a fixed template.
Lines at the outer eye produced by orbicularis oculi activity. A lower-concentration dilution is often preferred here — the muscle is thin and superficial, so placement precision matters more than total dose.
Lines produced by frontalis activity. Treated conservatively and usually alongside the glabella, because the frontalis is the muscle that holds the brow up.
Selective treatment of the depressor muscles to let the frontalis lift the lateral brow. A technique-led application that depends entirely on accurate muscle selection rather than on product choice.
Botulinum toxin products are prescription-only medicines. Any use outside the indications approved in your jurisdiction is a clinical decision made by the treating practitioner under their own professional judgement and local regulatory framework. Korea Filler Experts supplies the product; nothing here should be read as a recommendation to treat any medical condition.
What is inside AxeniQ 100UI
| Active substance | Clostridium botulinum toxin type A |
| Strength | 100 Units per vial |
| Stabiliser | Human serum albumin, 0.5 mg |
| Tonicity agent | Sodium chloride, 0.9 mg |
| Batch verification | SDS-PAGE protein profile analysis |
| Pharmaceutical form | Vacuum-dried powder for solution for injection |
| Diluent | Preservative-free 0.9% sodium chloride injection (not supplied) |
| Container | Single-use glass vial |
| Route | Intramuscular injection |
| Developed by | Genèse Labs, Paris, France |
| Regulatory class | Prescription-only medicine (professional use) |
Reading the carton
Before you accept a delivery, check four things:
- The unit count matches what you ordered — AxeniQ comes in 100 U and 200 U.
- The lot / batch number on the carton matches the number printed on the vial.
- The expiry date leaves you enough working life — we do not dispatch stock with under 6 months remaining unless agreed in advance.
- The carton arrived cold, with the coolant pack still chilled.
Vial looks empty? Vacuum drying leaves the contents as a thin film rather than a visible cake. This is expected and is not a sign of a short fill.
What each component does
- Botulinum toxin type A — the active substance. It temporarily reduces the release of acetylcholine at the neuromuscular junction, lowering activity in the injected muscle.
- Human serum albumin, 0.5 mg — stabilises the toxin protein through drying, storage and reconstitution. Without a stabiliser the protein would adsorb to the glass and lose potency. This is a human blood derivative; if a patient raises that specifically, an albumin-free product such as Coretox or Innotox is the alternative.
- Sodium chloride, 0.9 mg — brings the reconstituted solution to a tonicity suitable for injection.
What SDS-PAGE actually tests
SDS-PAGE — sodium dodecyl sulfate polyacrylamide gel electrophoresis — pulls a protein sample through a gel under an electric field. Smaller proteins travel further, so the sample resolves into bands by molecular weight.
For a botulinum toxin batch, that gives a fingerprint: the bands should appear where the neurotoxin and its accessory proteins are expected. Missing or extra bands would indicate degradation, fragmentation or contamination. Running it on each batch is a reasonable integrity check and a legitimate thing to publish.
What it is not: a measure of how much active toxin is present or how well it will work. Potency is established by a separate assay, and clinical effect depends on dose and technique. Treat SDS-PAGE as evidence of manufacturing consistency rather than of clinical performance — that is the honest reading of it.
How it works
After intramuscular injection, botulinum toxin type A binds to receptors on presynaptic cholinergic nerve terminals and reduces the release of acetylcholine, the neurotransmitter that triggers muscle contraction. Activity in the injected muscle falls, and the movement producing a dynamic line decreases with it.
The effect is temporary. Nerve terminal function recovers over time, which is why treatment is repeated rather than permanent.
How to prepare and use AxeniQ 100UI
Reference information for licensed practitioners. Reconstitution and administration must follow the prescribing information approved in your market.
Step by step
-
Inspect the vial
Check the label, unit count, lot number and expiry date, and confirm the seal is intact. A vacuum-dried vial often looks empty — that is expected.
-
Choose your concentration
Decide the diluent volume before you start, based on the treatment areas planned for the session. The table below sets out common dilutions.
-
Introduce the diluent slowly
Insert the needle at an angle and let the vacuum draw the preservative-free 0.9% saline in. Direct the stream against the vial wall rather than onto the powder.
-
Disperse the powder fully
Rotate the vial slowly until the contents dissolve completely. Do not shake vigorously. The solution should be clear, colourless and free of particulates.
-
Record and use promptly
Note the reconstitution date and time on the vial, store at 2–8 °C, and use within the period stated in your approved prescribing information.
Dilution reference
| Diluent added | Units per 0.1 mL | Total volume |
|---|---|---|
| 1.0 mL | 10.0 U | 1.0 mL |
| 2.0 mL | 5.0 U | 2.0 mL |
| 2.5 mL | 4.0 U | 2.5 mL |
| 4.0 mL | 2.5 U | 4.0 mL |
| 5.0 mL | 2.0 U | 5.0 mL |
Administration notes
Materials needed: preservative-free 0.9% sterile saline, a sterile syringe with a fine-gauge needle, gloves and alcohol swabs. None of these are supplied with the vial.
On diffusion: how far a toxin spreads from the injection point is driven mainly by the volume injected and the technique used — a dilute preparation placed in a large bolus spreads further than a concentrated one placed precisely. Choose the dilution with that in mind rather than relying on brand positioning.
- Units of botulinum toxin are product-specific. Do not convert or substitute units between brands.
- Dose per site, total dose and injection technique must follow the prescribing information approved in your market.
- Draw reconstituted product immediately before injection.
- Single-patient use. Discard any unused portion rather than carrying it to the next appointment.
- Treatment intervals should not be shortened below the minimum stated in the prescribing information.
After treatment
- Avoid rubbing or massaging the treated area for at least 24 hours
- Stay upright and avoid lying down for 4 to 6 hours
- Avoid strenuous exercise for 24 to 48 hours
- Avoid saunas, hot tubs and excessive sun exposure for at least 24 hours
- Mild redness, swelling or bruising can occur and usually settles within a few days
Storing and handling AxeniQ 100UI
Store refrigerated at 2–8 °C in the original carton, protected from light. Do not freeze. Always work to the expiry date printed on the carton.
Keep at 2–8 °C and use within the period stated in your approved prescribing information. Reconstitute only with preservative-free sterile 0.9% saline. Single-patient use only.
Transfer stock into a monitored medical refrigerator on arrival and keep a temperature log. If a shipment arrives warm, photograph the packaging and contact us before putting it into clinical service.
Do not use the vial if the contents are discoloured, if the reconstituted solution is cloudy or contains particles, if the expiry date has passed, or if the cold chain is known to have been broken. Single use only — do not reuse or resterilise. Dispose of unused product and used vials as clinical waste in line with local requirements.
What's included with AxeniQ 100UI
Diluent (0.9% sodium chloride injection), syringes and needles are not supplied with this product and must be sourced separately.
AxeniQ 100UI — frequently asked questions
What is AxeniQ 100UI?
AxeniQ 100UI is a botulinum toxin type A product developed by Genèse Labs of Paris, France. It is supplied as a vacuum-dried powder in a single 100-unit vial and reconstituted with preservative-free 0.9% sodium chloride before injection by a licensed practitioner.
Is AxeniQ a Korean product?
No. Genèse Labs is French, based in Paris, and the brand materials describe AxeniQ as developed with French aesthetic expertise.
That makes it unusual in our range, where most lines are Korean in origin. If a patient asks where their product comes from, this is one you can answer with something other than South Korea.
What is SDS-PAGE testing and why does Genèse Labs mention it?
SDS-PAGE is gel electrophoresis: a protein sample is pulled through a gel by an electric field, and the proteins separate into bands by molecular weight. The resulting pattern is a fingerprint of what is in the sample.
Run on each batch, it confirms the toxin complex has its expected protein profile and has not fragmented or degraded. It is a genuine integrity check — but it measures protein identity, not potency or clinical effect.
Does SDS-PAGE mean the product is more potent or works better?
No, and we would rather say so than let the impression stand. Potency is set by a separate assay that every batch must pass regardless, and clinical result depends on dose, dilution and placement.
What SDS-PAGE supports is a claim about manufacturing consistency. That is worth something, but it is not a performance claim.
How much saline do I add?
That depends on the concentration you want. Adding 2.5 mL of preservative-free 0.9% saline to a 100-unit vial gives 4 units per 0.1 mL, which is the most commonly used reference dilution. The table on this page lists other volumes.
Genèse Labs describes a "controlled diffusion profile". What does that mean in practice?
It is the manufacturer’s positioning, and we present it as that rather than as a measured specification — we have not seen comparative diffusion data for AxeniQ against another brand.
What is well established is that spread from the injection point is driven mainly by injected volume and technique: a dilute solution in a large bolus travels further than a concentrated one placed precisely. So the control you have over diffusion is mostly in the dilution table on this page and in your own hands.
What is the difference between the 100 U and 200 U vials?
Only how many units are in the vial — the formulation is the same. The 100 U suits face-focused lists; the 200 U reduces how many vials you open when treating larger muscle groups. The 200 U needs double the saline for the same concentration.
Does it contain human serum albumin?
Yes, 0.5 mg per vial, used as the stabiliser. Albumin is a human blood derivative. If a patient raises that specifically, Coretox and Innotox are albumin-free alternatives we also supply.
Can I substitute AxeniQ units for another brand's units?
No. Units of botulinum toxin are specific to each product and are not interchangeable between brands. Dosing must be taken from the prescribing information for the product in your hand.
What shelf life will my stock have?
We do not dispatch stock with less than six months of remaining shelf life unless you have specifically agreed to it. If you need a particular expiry window, tell us before you order and we will allocate accordingly.
What happens if my shipment arrives warm?
Do not use it. Photograph the outer box, the insulated liner, the coolant packs and the vial carton, and contact us the same day with your order number. We will review the cold-chain evidence and arrange a replacement where the failure occurred in transit.
Who is allowed to buy this product?
Botulinum toxin is a prescription-only medicine. Purchase and use are restricted to licensed healthcare professionals qualified to prescribe or administer injectable prescription medicines in their jurisdiction, with appropriate training in the relevant anatomy and injection technique. We do not sell to consumers.




